Analytical Data
-
Gene name
HLA-A*03:01&B2M&KRAS WT(VVVGAGGVGK) Tetramer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
NP_002107.3 (G25-T305)&P61769
-
Expression Region
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVVGAGGVGK
-
Molecular Weight
260-265 kDa under Non reducing (N)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*03:01, β2-microglobulin (B2M), and KRAS wild type (WT) tetramer recombinant proteins holds significant potential in cancer immunotherapy and diagnostic research. HLA-A*03:01 is a prevalent human leukocyte antigen (HLA) class I molecule, crucial for presenting peptides derived from intracellular proteins to CD8+ T cells, thereby initiating immune responses against aberrant cells, including cancerous ones. B2M is essential for the stability and surface expression of HLA class I molecules, playing a vital role in the immune surveillance process. In particular, KRAS is a well-known oncogene frequently mutated in various cancers; however, the wild type (WT) form remains relevant in the context of immune recognition. The use of tetramers consisting of HLA-A*03:01, B2M, and KRAS WT-derived peptides (such as VVVGAGGVGK) serves as a powerful tool for identifying and quantifying specific T cell populations that target tumors expressing KRAS WT peptides. This research could enhance our understanding of T cell-mediated immune responses in cancer, providing valuable insights for the development of personalized immunotherapies and improving early detection of tumor-associated T cell responses in patients. Ultimately, the exploration of these recombinant proteins aims to contribute to more effective cancer treatment strategies and the advancement of immunological research methodologies.
